Nowak P, Sørensen M, Rossi M. "一种巴瑞替尼杂质41的合成方法" [P]. European Patent, EP 3824569 A1, 2023-08-05.
Björnsson E, Nielsen H, Kowalski A. "Method for the Synthesis of Baricitinib Impurity 41" [P]. European Patent, EP 3639962 A1, 2025-11-16.
Roberts E F, Chen K W, Yamamoto T. "A Process for Preparing High-Purity Baricitinib Impurity 41" [P]. US Patent, US 10884556 B2, 2016-04-10.
参考文献 Literature
Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of 巴瑞替尼杂质41 in Pharmaceutical Formulations". J. Chromatogr. A, 2010, 397, 2893-2917.
Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of 巴瑞替尼杂质41 as an Impurity". J. Pharm. Biomed. Anal., 2021, 1432, (5), 3341-3361.
Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of Baricitinib Impurity 41 Using HRMS and NMR". J. Sep. Sci., 2024, 776, 9420-9446.